Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in treatment of peritoneal metastatic gastric cancer: current status and future prospects

doi:10.16139/j.1007-9610.2021.01.003

Abstract

CLC Number:

R735.2

JI Zhonghe, LI Yan. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in treatment of peritoneal metastatic gastric cancer: current status and future prospects[J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 11-16.

Figures/Tables 4

References 31

[1]	姬忠贺, 李鑫宝, 于洋, 等. 开拓临床肿瘤实践前沿创建腹膜肿瘤学科[J]. 中国肿瘤临床, 2020, 47(3):110-113.
[2]	Spratt JS, Adcock RA, Muskovin M, et al. Clinical delive-ry system for intraperitoneal hyperthermic chemotherapy[J]. Cancer Res, 1980, 40(2):256-260. pmid: 6766084
[3]	Sugarbaker PH. Peritonectomy procedures[J]. Ann Surg, 1995, 221(1):29-42. pmid: 7826158
[4]	Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis[J]. Cancer Treat Res, 1996, 82:359-374. pmid: 8849962
[5]	Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutio-nal study[J]. J Clin Oncol, 2004, 22(16):3284-3292. pmid: 15310771
[6]	Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase Ⅲ randomized clinical trial[J]. Ann Surg Oncol, 2011, 18(6):1575-1581.
[7]	van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer[J]. N Engl J Med, 2018, 378(3):230-240.
[8]	Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study[J]. Cancer, 2000, 88(2):358-363. pmid: 10640968
[9]	Thomassen I, van Gestel YR, van Ramshorst B, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors[J]. Int J Cancer, 2014, 134(3):622-628. doi: 10.1002/ijc.28373 pmid: 23832847
[10]	Ji ZH, Peng KW, Yu Y, et al. Current status and future prospects of clinical trials on CRS + HIPEC for gastric cancer peritoneal metastases[J]. Int J Hyperthermia, 2017, 33(5):562-570.
[11]	Desiderio J, Chao J, Melstrom L, et al. The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer[J]. Eur J Cancer, 2017, 79:1-14. doi: S0959-8049(17)30868-7 pmid: 28456089
[12]	Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis[J]. J Clin Oncol, 2019, 37(23):2028-2040.
[13]	Hong SH, Shin YR, Roh SY, et al. Treatment outcomes of systemic chemotherapy for peritoneal carcinomatosis arising from gastric cancer with no measurable disease: retrospective analysis from a single center[J]. Gastric Cancer, 2013, 16(3):290-300.
[14]	Yonemura Y, Fujimura T, Nishimura G, et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination[J]. Surgery, 1996, 119(4):437-444.
[15]	Fujimoto S, Takahashi M, Mutou T, et al. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery[J]. Cancer, 1997, 79(5):884-891. pmid: 9041149
[16]	Hall JJ, Loggie BW, Shen P, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer[J]. J Gastrointest Surg, 2004, 8(4):454-463.
[17]	Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer[J]. Arch Surg, 2004, 139(1):20-26.
[18]	Yonemura Y, Kawamura T, Bandou E, et al. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion[J]. Br J Surg, 2005, 92(3):370-375.
[19]	Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy[J]. Ann Surg Oncol, 2010, 17(9):2370-2377.
[20]	Canbay E, Mizumoto A, Ichinose M, et al. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan[J]. Ann Surg Oncol, 2014, 21(4):1147-1152. doi: 10.1245/s10434-013-3443-2 pmid: 24356799
[21]	Desantis M, Bernard JL, Casanova V, et al. Morbidity, mortality, and oncological outcomes of 401 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC)[J]. Langenbecks Arch Surg, 2015, 400(1):37-48.
[22]	Boerner T, Graichen A, Jeiter T, et al. CRS-HIPEC prolongs survival but is not curative for patients with peritoneal carcinomatosis of gastric cancer[J]. Ann Surg Oncol, 2016, 23(12):3972-3977. pmid: 27313067
[23]	Passot G, Vaudoyer D, Villeneuve L, et al. What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 procedures[J]. J Surg Oncol, 2016, 113(7):796-803.
[24]	Rihuete Caro C, Manzanedo I, Pereira F, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis[J]. Eur J Surg Oncol, 2018, 44(11):1805-1810.
[25]	Manzanedo I, Pereira F, Rihuete Caro C, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish Group of Peritoneal Oncologic Surgery (GECOP)[J]. Ann Surg Oncol, 2019, 26(8):2615-2621. doi: 10.1245/s10434-019-07450-4 pmid: 31115852
[26]	姬忠贺, 于洋, 刘刚, 等. 肿瘤细胞减灭术加腹腔热灌注化疗治疗胃癌腹膜转移的预后列线图构建与验证[J]. 中华普通外科杂志, 2019, 34(10):833-836.
[27]	Yonemura Y, Prabhu A, Sako S, et al. Long term survival after cytoreductive surgery combined with perioperative chemotherapy in gastric cancer patients with peritoneal metastasis[J]. Cancers (Basel), 2020, 12(1):116.
[28]	Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: management of gastric metastases[J]. Cancer, 2020, 126(11):2541-2546.
[29]	Coccolini F, Cotte E, Glehen O, et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials[J]. Eur J Surg Oncol, 2014, 40(1):12-26. doi: 10.1016/j.ejso.2013.10.019 pmid: 24290371
[30]	姬忠贺, 刘刚, 安松林, 等. 完全肿瘤细胞减灭术加腹腔热灌注化疗治疗胃癌腹膜转移的病例筛选策略[J]. 中国肿瘤临床, 2020, 47(3):128-134.
[31]	Brenkman HJF, Päeva M, van Hillegersberg R, et al. Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer-a systematic review[J]. J Clin Med, 2019, 8(10):1658.

作者	n	中位生存期（月）	生存率（%）
作者	n	中位生存期（月）	1年	3年	5年
Bonnot等^[12]	180	18.8	/	26.2	19.9
Yonemura等^[14]	83	/	43.0	/	11.0
Fujimoto等^[15]	48	14.1	54.0	41.5	31.0
Hall等^[16]	34	8.0	27.0	/	6.0
Glehen等^[17]	49	10.3	48.1	/	16.0
Yonemura等^[18]	107	11.5	/	/	6.7
Glehen等^[19]	159	9.2	43.0	18.0	13.0
Canbay等^[20]	194	15.8	66.0	/	10.7
Desantis等^[21]	14	13.3	/	21.6	21.6
Boerner等^[22]	38	17.2	71.1	24.1	6.4
Passot等^[23]	127	13.0	/	/	14.0
Rihuete Caro等^[24]	35	16.0	70.8	21.3	21.3
Manzanedo等^[25]	88	21.2	79.9	30.9	27.5
姬忠贺等^[26]	115	13.1	56.5	12.6	8.1
Yonemura等^[27]	419	/	/	/	9.6

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in treatment of peritoneal metastatic gastric cancer: current status and future prospects

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 31

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	YAN Chao, LU Sheng, YAN Min, ZHU Zhenggang. Chinese interpretation of Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition) and Ruijin clinical practice [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 326-354.
[2]	SUN Qi, HUANG Wenbo, HE Bingliang, LIU Chang, XU Yuhang, ZHAO Wei. Efficacy with prognostic value of postoperative prophylactic hyperthermic intraperitoneal chemotherapy for locally advanced gastric cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 366-370.
[3]	SUN Qiang, YAO Jun, ZHANG Xin, DU Shanshan, WANG Weijun. Research progress of anti reflux digestive tract reconstruction for proximal gastrectomy [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 388-393.
[4]	YAN Su, ZHENG Minhua. Practice of single-port and reduced-port laparoscopic gastric cancer surgery in China [J]. Journal of Surgery Concepts & Practice, 2023, 28(03): 233-239.
[5]	HU Wenqing, YANG Yinhao, CUI Peng, WEI Wei. Current status of high-positioned digestive tract reconstruction after laparoscopic proximal stomach and lower esophagus resection through the abdominal-left diaphragmatic approach for adenocarcinoma of esophagogastric junction [J]. Journal of Surgery Concepts & Practice, 2023, 28(03): 226-232.
[6]	FAN Qingquan, SONG Xiaoling, GU Jun. Exosome in gastric cancer: research and perspective [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 177-180.
[7]	DENG Shijie, YUAN Fei. Advances in diagnosis and molecular detection of EBV-positive gastric cancer and gastric cancer with lymphoid stroma [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 53-57.
[8]	ZHANG Huan, CHEN Yong. New progression of radiomics in diagnosis of gastric cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 42-48.
[9]	LIU Wentao, LIU Fukun. Summary and prospect of perioperative comprehensive treatment for gastric cancer in China [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 36-41.
[10]	LI Guoli, GUO Feilong. Preoperative chemotherapy through intra-arterial combined with intra-venous administration in treatment of advanced gastric cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 31-35.
[11]	ZHAO Fazhi, ZHAO Ping. Formation and improvement of surgery-based treatment system for gastric cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 24-30.
[12]	LU Yiming, XIONG Jianping, TIAN Yantao. Current status and prospect of conversion therapy for far-advanced gastric cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 17-23.
[13]	LI Jianfang, YU Junxian, YAN Chao, ZHU Zhenggang, LIU Bingya. Hotspots in basic and translational research of gastric cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 7-16.
[14]	ZHU Zhenggang. Progress and prospect of surgical comprehensive treatment of gastric cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 1-6.
[15]	LUO Xi, SHI Yongmei, CHEN Ke, JIANG Shuo, WU Yuwei. Analysis on evaluation of patients with gastric and colon cancer using modified patient-generated subjective global assessment [J]. Journal of Surgery Concepts & Practice, 2022, 27(06): 545-550.